388
Participants
Start Date
August 25, 2016
Primary Completion Date
December 10, 2020
Study Completion Date
January 24, 2022
JNJ-64304500
Participants will receive JNJ-64304500 Subcutaneously.
Placebo
Participants will receive placebo Subcutaneously.
Ustekinumab
Participants will receive ustekinumab as per the dosing regimen.
Lone Tree
Coral Gables
Kissimmee
Miami
Miramar
Orlando
Winter Park
Marietta
Chicago
Evanston
Indianapolis
Houma
Lake Charles
Shreveport
Columbia
Morristown
Brooklyn
Great Neck
New York
Rochester
Charlotte
Raleigh
Cincinnati
Cleveland
Doylestown
Columbia
Greenville
Nashville
Houston
Richardson
San Antonio
Southlake
Tyler
Salt Lake City
Fairfax
Richmond
Seattle
Brussels
Ghent
Liège
Sofia
Brandon
London
Amiens
Lille
Marseille
Paris
Pierre-Bénite
Saint-Etienne
Toulouse
Berlin
Essen
Hamburg
Hanover
Heidelberg
Kiel
Leipzig
Ludwigshafen
Lübeck
Lüneburg
Ulm
Budapest
Debrecen
Szekszárd
Szombathely
Asahikawa
Chikushino-shi
Fukushima
Gunma
Hamamatsu
Hirosaki
Hitachi
Hyôgo
Isehara
Kagoshima
Kahoku-gun
Kamakura
Kanagawa
Kanazawa
Kashiwa
Midori-ku
Minatoku
Niigata
Okinawa
Osaka
Ōsaka-sayama
Saga
Sakura
Sapporo
Sendai
Shimotsuga Gun
Shimotsuke
Shinjuku Ku
Shinjuku-ku
Sunto-gun
Bydgoszcz
Chorzów
Krakow
Ksawerów
Lodz
Oświęcim
Poznan
Sopot
Szczecin
Warsaw
Wroclaw
Włocławek
Bucharest
Oradea
Timișoara
Irkutsk
Kazan'
Krasnoyarsk
Moscov
Moscow
Nizhny Novgorod
Novosibirsk
Omsk
Rostov-on-Don
Saint Petersburg
Samara
Tosno
Yekaterinburg
Bundang
Busan
Daegu
Guri-si
Gyeonggi-do
Seoul
Suwon
Chernivtsi
Dnipropetrovsk
Ivano-Frankivsk
Kharkiv
Kiyv
Kropyvnytskyi
Kyiv
Lviv
Sumy
Ternopil
Uzhhorod
Zaporizhzhia
Zhaporozhia
Cambridge
Nottingham
Sheffield
Sutton in Ashfield
Janssen Research & Development, LLC
INDUSTRY